Extended Data Fig. 6. Cryptic HDGFL2 can be detected by a different MSD assay in CSF of both presymptomatic and symptomatic C9orf72 mutation carriers.
(A) Original sandwich ELISA using Meso Scale Discovery (MSD) system. (B) Elevated cryptic HDGFL2 levels are detected in presymptomatic (n = 34 CSF samples, mean = 665.4, SD = 142.5, p = 0.0009) and symptomatic (n = 54 CSF samples, mean = 758.4, SD = 152.2, p = 3.3x10−7) C9orf72 mutation carriers compared to controls (n = 10 CSF samples, mean = 451.4, SD = 178.8). Elevated cryptic HDGFL2 levels are not found in the small cohort of sporadic ALS (n = 6 CSF samples, mean = 513.0, SD = 154.7, p = 0.86). The box extends from the 25th to the 75th percentile, with the middle line at the median. The whiskers extend from the minimum to the maximum. Analysis performed with one-way ANOVA with Tukey’s multiple comparisons test. *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001. (C) Cryptic HDGFL2 detection by our MSD assay in CSF of C9orf72 mutation carriers diagnosed with ALS, FTD, or ALS-FTD tends to be higher during the earlier stage of symptomatic disease. Pearson correlation (two-tailed), r = −0.30, p = 0.027.